Acumen Pharmaceuticals (ABOS) Stock Analysis

What Acumen Pharmaceuticals does

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.

Key metrics

ETFs linked to ABOS

Broad-market and Healthcare sector ETFs an investor holding Acumen Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ABOS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Acumen Pharmaceuticals?

Acumen Pharmaceuticals trades under the ticker ABOS on NASDAQ.

Which exchange is ABOS listed on?

ABOS is listed on NASDAQ.

What sector does Acumen Pharmaceuticals operate in?

Acumen Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ABOS in a portfolio?

PortView shows ABOS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.